Chorioamnionitis/funisitis and the development of bronchopulmonary dysplasia.
OBJECTIVE
To examine the association between chorioamnionitis with or without funisitis and bronchopulmonary dysplasia in infants less than 30 completed weeks gestation given the current standards of antenatal steroid and surfactant use.


METHODS
Infants included in the study were those delivered at less than 30 completed weeks gestation from January 1996 to July 2001, identified from a prospectively managed database. Placental pathology was reviewed for the presence or absence of chorioamnionitis and funisitis. Infants were divided into three groups depending on degree of exposure to fetal inflammation (no inflammation, chorioamnionitis only and chorioamnionitis and funisitis). Data relating to gestational age, sex, antenatal steroid exposure, surfactant treatment, days of positive pressure ventilation and days of oxygen required were collected. Bronchopulmonary dysplasia was defined as death due to respiratory failure or any oxygen requirement at 36 weeks postmenstrual age.


RESULTS
Two hundred and forty-one infants were included in the study. The mean gestational age was 27.7 weeks and mean birthweight 1089 g. One hundred and sixty-one infants were not exposed to any in utero inflammation, 40 showed chorioamnionitis and 40 showed chorioamnionitis and funisitis. There was no significant difference between antenatal steroid and surfactant treatment between the three groups. There was no significant difference between the three groups in the development of bronchopulmonary dysplasia. Low gestational age was the most significant predictor of developing bronchopulmonary dysplasia.


CONCLUSIONS
The risk of developing bronchopulmonary dysplasia is not increased following exposure to chorioamnionitis or funisitis in the context of current antenatal steroid and surfactant use. The most significant predictor for developing bronchopulmonary dysplasia is gestational age at the time of delivery.
Kent
A
A
Department of Neonatology, The Canberra Hospital, Canberra, Australian Capital Territory, New Sout Wales, Australia. alison.kent@act.gov.au
Dahlstrom
J E
JE
D001623:Betamethasone / Q000009:adverse effects; D001997:Bronchopulmonary Dysplasia / Q000209:etiology*; D002821:Chorioamnionitis / Q000150:complications*; D016208:Databases, Factual; D003907:Dexamethasone / Q000009:adverse effects; D005260:Female; D005865:Gestational Age; D005938:Glucocorticoids / Q000009:adverse effects; D006801:Humans; D007231:Infant, Newborn; D007234:Infant, Premature; D016015:Logistic Models; D008297:Male; D010100:Oxygen / Q000008:administration & dosage; D010920:Placenta / Q000473:pathology*; D011247:Pregnancy; D011446:Prospective Studies
D005938:Glucocorticoids; D003907:Dexamethasone; D001623:Betamethasone; D010100:Oxygen